A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates - PubMed (original) (raw)
A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates
Andrew D Hislop et al. J Exp Med. 2007.
Abstract
gamma 1-Herpesviruses such as Epstein-Barr virus (EBV) have a unique ability to amplify virus loads in vivo through latent growth-transforming infection. Whether they, like alpha- and beta-herpesviruses, have been driven to actively evade immune detection of replicative (lytic) infection remains a moot point. We were prompted to readdress this question by recent work (Pudney, V.A., A.M. Leese, A.B. Rickinson, and A.D. Hislop. 2005. J. Exp. Med. 201:349-360; Ressing, M.E., S.E. Keating, D. van Leeuwen, D. Koppers-Lalic, I.Y. Pappworth, E.J.H.J. Wiertz, and M. Rowe. 2005. J. Immunol. 174:6829-6838) showing that, as EBV-infected cells move through the lytic cycle, their susceptibility to EBV-specific CD8(+) T cell recognition falls dramatically, concomitant with a reductions in transporter associated with antigen processing (TAP) function and surface human histocompatibility leukocyte antigen (HLA) class I expression. Screening of genes that are unique to EBV and closely related gamma 1-herpesviruses of Old World primates identified an early EBV lytic cycle gene, BNLF2a, which efficiently blocks antigen-specific CD8(+) T cell recognition through HLA-A-, HLA-B-, and HLA-C-restricting alleles when expressed in target cells in vitro. The small (60-amino acid) BNLF2a protein mediated its effects through interacting with the TAP complex and inhibiting both its peptide- and ATP-binding functions. Furthermore, this targeting of the major histocompatibility complex class I pathway appears to be conserved among the BNLF2a homologues of Old World primate gamma 1-herpesviruses. Thus, even the acquisition of latent cycle genes endowing unique growth-transforming ability has not liberated these agents from evolutionary pressure to evade CD8(+) T cell control over virus replicative foci.
Figures
Figure 1.
Diagrammatic alignment of the right-hand ends of the sequenced γ1-herpesviruses. ORFs of EBV, the rhesus LCV, and marmoset LCV are shown as boxes; closed symbols represent ORFs with homologues in other herpesviruses; open symbols represent genes found only in γ1-herpesviruses; and hatched symbols represent latent genes.
Figure 2.
Representative cytotoxicity assays testing recognition of target cells coexpressing EBV-unique genes and target proteins. (A) Epithelial cells (top) were infected with vaccinia viruses expressing EBNA3A (vAntigen) and combinations of the indicated viruses expressing genes unique to EBV or a control vaccinia virus lacking an inserted gene (vTk−), before being incubated with HLA-B*0801–restricted CD8+ T cell clones specific for EBNA3A. EBV-transformed B cells (middle and bottom) were coinfected with modified vaccinia Ankara expressing invariant chain–targeted EBNA3C (vAntigen) and the indicated combinations of vaccinia viruses. In parallel assays, the infected B cells were incubated with either HLA-B*2705–restricted CD8+ T cell clones specific for EBNA3C (middle) or CD4+ T cell clones restricted by HLA DQ5 specific for EBNA3C (bottom). (B) EBV-transformed B cells were infected with vaccinia viruses expressing BNLF2a, and the different EBV antigens indicated (vAntigen) encoding epitopes presented through a range of HLA types. Infected cells were incubated with cognate CD8+ T cells specific for an HLA-A*0201 epitope encoded by BMLF1, an HLA-A*2402 epitope encoded by BMRF1, an HLA-B*38 epitope encoded by EBNA2, an HLA-B*2705 epitope encoded by EBNA3B, an HLA-B*0801 epitope encoded by BZLF1, or an HLA-C*0101 epitope encoded by BGLF4. Error bars represent means ± SD.
Figure 3.
Expression of BNLF2a prevents CD8+ T cell recognition by disrupting antigen presentation. (A) MJS cells were retrovirally transduced to express BNLF2aHA (bottom) or control GFP (top). These cells were either infected with vaccinia viruses expressing BZLF1 or a control TK− virus, or sensitized with RAKFKQLL peptide or DMSO as a control before being incubated with CD8+ T cells specific for the BZLF1-encoded RAKFKQLL epitope in 5-h cytotoxicity assays. Error bars represent means ± SD. (B) Flow cytometry histograms of the same cell lines show surface staining for HLA class I (B9.12.1) and HLA class II (L243), or staining with an isotype control. (C) Lysates of the two cell lines were separated by SDS-PAGE and analyzed by immunoblotting with antibodies specific for the HA tag (12CA5), TAP1 (148.3), TAP2 (435.4), tapasin (7F6), HLA class I heavy chains (HC10), and HLA class II DRα chains (DA6-147).
Figure 4.
EBV BNLF2a blocks peptide transport by TAP. (A) TAP-dependent peptide transport in BNLF2aHA-expressing and control MJS cells was assessed by permeabilizing the cells with streptolysin O and incubating them with a fluoresceinated peptide in the presence or absence of ATP. Translocated peptides that had become glycosylated in the endoplasmic reticulum were recovered by adsorption to concanavalin A–sepharose beads. After elution, the recovered peptide was quantitated by fluorometry in arbitrary units. Error bars represent the SEM of triplicates in a representative experiment. (B) Digitonin lysates of BNLF2aHA- expressing and control MJS-GFP cells were subjected to immunoprecipitation (IP) with antibodies specific for TAP1 (148.3), TAP2 (435.4), tapasin (R.gp46C), HLA class I heavy chains (HC10), and HLA class II DRα chains (DA6-147). Cell lysates and immune complexes were separated by SDS-PAGE, followed by Western blot analysis and staining with anti-HA antibody (12CA5) to detect HA-tagged BNLF2a.
Figure 5.
EBV BNLF2a inhibits peptide and ATP binding to TAP. (A) Microsomes prepared from BNLF2aHA-expressing and control MJS cells were incubated with a radiolabeled model peptide; where indicated, an excess of ICP47 competitor peptide was included in this incubation. After UV cross-linking, microsomes were lysed, and the proteins were separated by SDS-PAGE and exposed to a phosphoimaging screen. The position where TAP1 migrated in parallel immunoprecipitation experiments is shown by the arrowhead. The asterisk denotes a nonspecific background band. (B) Quantification of triplicate bands representing TAP-bound peptide. Results are shown as the percentage of peptide binding relative to peptide binding in control MJS cells (set as 100%). Error bars represent means ± SD. (C) Digitonin and NP-40 lysates of MJS-BNLF2aHA and control MJS-GFP cells were incubated with ATP-agarose beads. ATP-agarose–bound (pellet) and unbound (supernatant) protein fractions were separated by SDS-PAGE and immunoblotted. Membranes were probed with antibodies specific for TAP1 (148.3), TAP2 (435.4), tapasin (7F6), HLA class I heavy chain (HC10), and the HA tag (12CA5).
Figure 6.
Old World primate γ1-herpesvirus BNLF2a sequence and function. (A) The BNLF2 regions from the indicated herpesviruses were sequenced, and the predicted amino acid sequence of the BNLF2a genes are shown. Black regions represent regions of homology between the different BNLF2a species, whereas gray-shaded regions represent conservative amino acid changes. (B) BNLF2a genes were subcloned into plasmid expression vectors that coexpressed GFP, and these were transiently transfected into MJS cells. At 48 h, surface levels of HLA class I and class II were assessed on GFP-positive cells by staining with the relevant antibody and analyzing the cells by flow cytometry. Black histograms represent surface marker intensity of cells transfected with the relevant BNLF2a, whereas open histograms represent the intensity of cells transfected with the empty vector plasmid.
Similar articles
- Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle.
Croft NP, Shannon-Lowe C, Bell AI, Horst D, Kremmer E, Ressing ME, Wiertz EJ, Middeldorp JM, Rowe M, Rickinson AB, Hislop AD. Croft NP, et al. PLoS Pathog. 2009 Jun;5(6):e1000490. doi: 10.1371/journal.ppat.1000490. Epub 2009 Jun 26. PLoS Pathog. 2009. PMID: 19557156 Free PMC article. - Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation.
Horst D, van Leeuwen D, Croft NP, Garstka MA, Hislop AD, Kremmer E, Rickinson AB, Wiertz EJ, Ressing ME. Horst D, et al. J Immunol. 2009 Feb 15;182(4):2313-24. doi: 10.4049/jimmunol.0803218. J Immunol. 2009. PMID: 19201886 - Cooperation between Epstein-Barr virus immune evasion proteins spreads protection from CD8+ T cell recognition across all three phases of the lytic cycle.
Quinn LL, Zuo J, Abbott RJ, Shannon-Lowe C, Tierney RJ, Hislop AD, Rowe M. Quinn LL, et al. PLoS Pathog. 2014 Aug 21;10(8):e1004322. doi: 10.1371/journal.ppat.1004322. eCollection 2014 Aug. PLoS Pathog. 2014. PMID: 25144360 Free PMC article. - Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products.
Ressing ME, Horst D, Griffin BD, Tellam J, Zuo J, Khanna R, Rowe M, Wiertz EJ. Ressing ME, et al. Semin Cancer Biol. 2008 Dec;18(6):397-408. doi: 10.1016/j.semcancer.2008.10.008. Epub 2008 Oct 25. Semin Cancer Biol. 2008. PMID: 18977445 Review. - The impact of HLA polymorphism on herpesvirus infection and disease.
Palmer WH, Norman PJ. Palmer WH, et al. Immunogenetics. 2023 Jun;75(3):231-247. doi: 10.1007/s00251-022-01288-z. Epub 2023 Jan 3. Immunogenetics. 2023. PMID: 36595060 Free PMC article. Review.
Cited by
- pUS6 in pseudorabies virus participates in the process of inhibiting antigen presentation by inhibiting the assembly of peptide loading complex.
Ma N, Sun Y, Ding C, Li Y, Yu L, Chen L. Ma N, et al. BMC Vet Res. 2024 Oct 9;20(1):454. doi: 10.1186/s12917-024-04294-3. BMC Vet Res. 2024. PMID: 39379944 Free PMC article. - Epstein-Barr virus: the mastermind of immune chaos.
Silva JM, Alves CEC, Pontes GS. Silva JM, et al. Front Immunol. 2024 Feb 7;15:1297994. doi: 10.3389/fimmu.2024.1297994. eCollection 2024. Front Immunol. 2024. PMID: 38384471 Free PMC article. Review. - Viral MicroRNAs in Herpes Simplex Virus 1 Pathobiology.
Naqvi RA, Valverde A, Yadavalli T, Bobat FI, Capistrano KJ, Shukla D, Naqvi AR. Naqvi RA, et al. Curr Pharm Des. 2024;30(9):649-665. doi: 10.2174/0113816128286469240129100313. Curr Pharm Des. 2024. PMID: 38347772 Review. - Mechanisms of T cell evasion by Epstein-Barr virus and implications for tumor survival.
Sausen DG, Poirier MC, Spiers LM, Smith EN. Sausen DG, et al. Front Immunol. 2023 Dec 21;14:1289313. doi: 10.3389/fimmu.2023.1289313. eCollection 2023. Front Immunol. 2023. PMID: 38179040 Free PMC article. Review. - Epstein-Barr virus: the molecular virology and the associated diseases.
Murata T. Murata T. Fujita Med J. 2023 May;9(2):65-72. doi: 10.20407/fmj.2022-018. Epub 2022 Oct 28. Fujita Med J. 2023. PMID: 37234394 Free PMC article.
References
- McGeoch, D.J., F.J. Rixon, and A.J. Davison. 2006. Topics in herpesvirus genomics and evolution. Virus Res. 117:90–104. - PubMed
- Sawtell, N.M., R.L. Thompson, L.R. Stanberry, and D.I. Bernstein. 2001. Early intervention with high-dose acyclovir treatment during primary herpes simplex virus infection reduces latency and subsequent reactivation in the nervous system in vivo. J. Infect. Dis. 184:964–971. - PubMed
- Hill, A., P. Jugovic, I. York, G. Russ, J. Bennink, J. Yewdell, H. Ploegh, and D. Johnson. 1995. Herpes simplex virus turns off the TAP to evade host immunity. Nature. 375:411–415. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- G0501074/MRC_/Medical Research Council/United Kingdom
- R37 AI026296/AI/NIAID NIH HHS/United States
- G9901249/MRC_/Medical Research Council/United Kingdom
- G9818340/MRC_/Medical Research Council/United Kingdom
- AI26296/AI/NIAID NIH HHS/United States
- R01 AI026296/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous